Trial Profile

Phase I study of FF-10501-01 in patients with Myelodysplastic Syndrome and continuous administration study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FF 10501 (Primary)
Indications Myelodysplastic syndromes
Focus Adverse reactions
Sponsors Toyama Chemical

Most Recent Events

28 Apr 2017 Status changed from recruiting to completed.
24 Dec 2015 According to a Strategia Therapeutics media release, a total of 5 dose cohorts (50-400 mg/m2 orally twice daily) have been enrolled. Additional Phase 1 dose cohorts of 500, 600 and 800 mg/m2 BID will be assessed. The Phase 2 portion of the study will open when a recommended Phase 2 dose is determined
24 Dec 2015 Interim results published at the 57th American Society of Hematology Meeting, according to a Strategia Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com